BACKGROUND
Although safe and effective human papillomavirus (HPV) vaccines have been available since 2006, national introduction in low- and middle-income countries (LMICs) has progressed slowly. HPV vaccine adoption may have been shaped by evolving World Health Organization (WHO) recommendations, funding policies of G...
Jiyeon Suh, M. Brisson, E. Burger et al.· Expert Review of Vaccines· 0 citations
Introduction Human papillomavirus (HPV) is a leading cause of both cervical and non-cervical cancers, including anal, oropharyngeal, vaginal and vulvar cancers. While most HPV vaccination impact assessments have focused on preventing cervical cancer among women, the broader benefits of vaccination against other HPV-att...
A. Tuli, M. Jit, K. Abbas et al.· BMJ Global Health· 0 citations
Infectious disease transmission models are governed by parameters informed by systematic review of epidemiological literature. Large language models (LLMs) could facilitate this, but the reliability of the results to inform models has not been tested. We built an open-source, end-to-end pipeline to simulate LLM perform...
X. Yang, C. Y. Lee, B. Quilty et al.· medRxiv· 0 citations
BACKGROUND
Therapeutic HPV vaccines (TxVs) may complement existing cervical cancer prevention strategies, particularly for women already infected with HPV who derive limited benefit from prophylactic vaccination. As China advances toward the WHO 90-70-90 cervical cancer elimination targets, understanding the potential...
Chenghao Pan, Shangying Hu, Tingting You et al.· BMC Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
